Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single‐tablet regimen in a multicentre cohort in Spain
Inés Suárez‐García(Centro de Investigación Biomédica en Red), Inmaculada Jarrín(Instituto de Salud Carlos III), Miguel Alberto de Zárraga Fernández(Hospital Universitario San Agustín), Cristina García Yubero(Hospital Universitario Infanta Sofía), Belén Alejos, Enrique Bernal(Honeywell (United States)), Laura Pérez‐Is, Cristina Moreno(Universidad de Alcalá), G. Abad(Hospital Universitario Miguel Servet), Zuriñe Zubero(Hospital de Basurto), Marta Ruiz‐Algueró(Instituto de Salud Carlos III)
Cited by 7
Related Papers
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
|Annals of Internal Medicine|2020|342
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
|International Journal of Infectious Diseases|2020|226
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
|European Respiratory Journal|2019|176
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
|Clinical Microbiology and Infection|2020|128